1. Inicio
  2. Publicaciones
  3. New developments in the management of hepatitis C virus infection: focus on boceprevir.

New developments in the management of hepatitis C virus infection: focus on boceprevir.

Fecha de publicación:

Autores de IIS La Fe

Grupos

Abstract

Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-a and ribavirin) has an effectiveness rate of only 40%-50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes.

Datos de la publicación

ISSN/ISSNe:
1177-5475, 1177-5491

Biologics : targets & therapy  Dove Medical Press Ltd

Tipo:
Article
Páginas:
249-256
PubMed:
22904616
Factor de Impacto:
0,845 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • HCV, antiviral therapy, protease inhibitors, viral resistance

Proyectos y Estudios Clínicos

ESTUDIO MULTICENTRICO, ALEATORIZADO DE 24 MESES DE DURACION QUE EVALUA LA EFICACIA, SEGURIDAD, TOLERABILIDAD Y FARMACOCINETICA DE SOTRASTAURINA (STN) COMBINADA CON TACROLIMUS (TAC) FRENTE A UN REGIMEN CONTROL BASADO EN TACROLIMUS/MICOFENOLATO MOFETIL (MMF ) EN RECEPTORES DE TRASPLANTE HEPATICO DE NOVO

Investigador Principal: RAFAEL LÓPEZ ANDÚJAR

CAEB071B2201 . 2011

VALIDACION DE UN CUESTIONARIO DE ADHERENCIA AL TRATAMIENTO EN PACIENTES CON INFECCION POR VIRUS DE LA HEPATITIS B. ESTUDIO HABIT.

Investigador Principal: MARTÍN PRIETO CASTILLO

IMI-VHB-2010-01 . 2011

Cita

Compartir